Display Settings:

Format

Send to:

Choose Destination
J Biomed Biotechnol. 2010;2010:237623. doi: 10.1155/2010/237623. Epub 2010 Jun 29.

Therapeutic cancer vaccines in combination with conventional therapy.

Author information

  • 1Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, 2730 Herlev, Denmark.

Abstract

The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data are emerging that strongly support the notion that combining immunotherapy with conventional therapies, for example, radiation and chemotherapy may improve efficacy. In particular combination with chemotherapy may lead to improved clinical efficacy by clearing suppressor cells, reboot of the immune system, by rendering tumor cells more susceptible to immune mediated killing, or by activation of cells of the immune system. In addition, a range of tumor antigens have been characterized to allow targeting of proteins coupled to intrinsic properties of cancer cells. For example, proteins associated with drug resistance can be targeted, and form ideal target structures for use in combination with chemotherapy for killing of surviving drug resistant cancer cells. Proteins associated with the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also simultaneously target cancer cells as well as suppressive cells in the tumor stroma.

PMID:
20617155
[PubMed - indexed for MEDLINE]
PMCID:
PMC2896846
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk